Clinical Trials Logo
  1. Home
  2. Kidney Transplantation
  3. NCT04803058
  4. Details
NCT04803058 Clinical Trial

A Study of TCD601 in the Induction of Tolerance in de Novo Renal Transplantation (PERSPECTIVE)

Kidney Transplantation Clinical Trial

Official title:
A Safety and Tolerability Study of TCD601 (Siplizumab), a Human Anti-CD2 Antibody, Combined With Donor Bone Marrow Cell Infusion and Non-myeloablative Conditioning, Including Fludarabine and Cyclophosphamide, for Tolerance Induction in de Novo Living Donor Renal Transplantation

Clinical Trial Details — Status: Recruiting

Administrative data
NCT number NCT04803058
Other study ID # TCD601A202
Secondary ID
Status Recruiting
Phase Phase 2
First received
Last updated
Start date December 14, 2022
Est. completion date December 2027

Study information
Verified date March 2024
Source ITB-Med LLC
Contact Shannon Zentmeyer, BSN
Phone 347-326-1985
Email shannon.zentmeyer@itb-med.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to evaluate if TCD601 can induce allogeneic tolerance in de novo living donor renal transplant recipients

Recruitment information / eligibility
Status Recruiting
Enrollment 12
Est. completion date December 2027
Est. primary completion date December 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 60 Years
Eligibility Key Inclusion Criteria: - Able to understand the study requirements and provide written informed consent before and study assessment is performed. - Male or female patients = 18 to 60 years of age. - Recipient of a first renal transplant from a non-HLA identical, but at least haploidentical, ABO compatible living donor. Key Exclusion Criteria: - Women of child-bearing potential - Subjects with a history of cancer - Donor-specific antibody

Study Design

Related Conditions & MeSH terms

Intervention

Biological:
• TCD601
Investigational Product

Locations
Country Name City State
Korea, Republic of Samsung Medical University Seoul
United States Massachusetts General Hospital Boston Massachusetts
United States University of Chicago Chicago Illinois
United States University of Texas Southwestern Medical Center Dallas Texas
United States Weill Cornell New York New York
United States Mayo Clinic Rochester Minnesota

Sponsors (1)
Lead Sponsor Collaborator
ITB-Med LLC

Countries where clinical trial is conducted

United States,  Korea, Republic of, 

Outcome
Type Measure Description Time frame Safety issue
Primary The safety, tolerability and activity of a Siplizumab-based conditioning regimen to induce renal allograft tolerance The proportion of patients off immunosuppression with good safety and tolerability 24 months
Secondary Incidence of biopsy proven acute rejection, death, and graft loss 24 months
Secondary The incidence of de novo DSA 24 months
See also
  Status Clinical Trial Phase
Recruiting NCT04910867 - APOL1 Genetic Testing Program for Living Donors N/A
Completed NCT02723591 - To Compare the Effects of Immediate-release Tacrolimus and Astagraf XL on Donor-Specific Antibody (DSA) Formation and the Development of Immune Activation (IA) in de Novo Kidney Transplant Recipients Phase 4
Completed NCT05945511 - Silent Gallbladder Stone in Kidney Transplantation Recipients: Should it be Treated?
Completed NCT02234349 - Bile Acids and Incretins in Pancreas Kidney Transplant Patients N/A
Completed NCT04496401 - PK Study in Diabetic Transplant récipients : From Twice-daily Tacrolimus to Once-daily Extended-release Tacrolimus Phase 4
Recruiting NCT05917795 - Endoscopic Sleeve Gastroplasty With Endomina® for the Treatment of Obesity in Kidney Transplant Candidates N/A
Not yet recruiting NCT05934383 - Safety and Efficacy of Ultrasound Renal Denervation in Kidney Transplantation Patients With Uncontrolled Hypertension N/A
Withdrawn NCT04936971 - Introduction of mTor Inhibitors and the Activation of the Cytomegalovirus (CMV) -Specific Cellular Immune Response Phase 4
Not yet recruiting NCT04540640 - Oxygenated Machine Preservation in Kidney Transplantation N/A
Not yet recruiting NCT03090828 - Economic Evaluation of an Education Platform for Patients With End-stage Renal Disease N/A
Recruiting NCT02908139 - Noninvasive Perioperative Monitoring of Arterial Stiffness, Volume and Nutritional Status in Stable Renal Transplant Recipients N/A
Completed NCT02560558 - Bela 8 Week Dosing Phase 4
Terminated NCT02417870 - Ultra-low Dose Subcutaneous IL-2 in Renal Transplantation Phase 1/Phase 2
Recruiting NCT02154815 - Pre-emptive Kidney Transplantation Quality of Life N/A
Completed NCT02235571 - iChoose Decision Kidney Aid for End-Stage Renal Disease Patients N/A
Enrolling by invitation NCT01905514 - ImPRoving Adherence to Immunosuppressive Therapy by Mobile Internet Application in Solid Organ Transplant Patients N/A
Completed NCT02147210 - Chronic Transplant Glomerulopathy and Regulation of Expression of Ephrin B1 N/A
Recruiting NCT01699360 - The Biomarker for Immunosuppressive Agents Metabolism in Chinese Renal Transplant Recipients Phase 4
Completed NCT01655563 - Pharmacogenetic Trial of Tacrolimus After Pediatric Transplantation Phase 2
Completed NCT01672957 - ORANGE Study: An Observational Study on Renal Function in Kidney Transplant Patients on Immunosuppressive Therapy Containing CellCept (Mycophenolate Mofetil) N/A